Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Recommendation of “Moderate Buy” from Analysts

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $87.3750.

KNSA has been the topic of a number of research reports. Canaccord Genuity Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Finally, JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $78.08 on Thursday. The company has a market cap of $6.01 billion, a price-to-earnings ratio of 80.49 and a beta of 0.05. Kiniksa Pharmaceuticals International has a one year low of $31.78 and a one year high of $82.94. The business’s fifty day moving average is $60.43 and its two-hundred day moving average is $51.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.30. The business had revenue of $243.60 million during the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, analysts predict that Kiniksa Pharmaceuticals International will post 1.38 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, Director G Bradley Cole sold 3,673 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the sale, the director owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. This represents a 23.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 51.98% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth about $31,000. KBC Group NV purchased a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth about $34,000. Smartleaf Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.